BREAKING: The American Society of Plastic Surgeons, an organization representing 92% of all board-certified plastic surgeons in the U.S., becomes the first major medical association to break from the consensus over “gender-affirming care” for minors.
This is big news. 🧵
2/ In the U.S., the use of puberty blockers, cross-sex hormones and surgeries to help kids who feel distressed about their developing bodies has depended on a perceived consensus of medical groups.
3/ Critics argue that the consensus is manufactured and enforced through suppression of alternative viewpoints and of evidence reviews. The @AmerAcadPeds, for instance, has suppressed member initiatives to get the group to conduct a systematic review of the evidence.
4/ The consensus of medical associations is a chief reason for the growing divide between the U.S. and Europe, where countries have reversed course on youth gender medicine after finding the evidence too weak to support the routine use of Rx.
5/ Court documents recently revealed that @wpath suppressed systematic reviews of evidence and eliminated age minimums for surgery under pressure from HHS’s Rachel Levine (@HHS_ASH). WPATH is the source of the U.S. consensus; its members helped write @TheEndoSociety guidelines.
6/ When I reached out to ASPS (@ASPS_News) for comment on the court/WPATH revelations, the group said it acknowledges the “low quality” nature of the evidence for Rx. It emphasized that it has never endorsed WPATH’s “standards of care” or the Endocrine Society’s 2017 CPG.
7/ ASPS also said it is currently “reviewing and prioritizing several initiatives,” presumably to provide members with better guidance.
8/ My piece also presents, for the first time, data on <18 gender surgeries from an ongoing @ManhattanInst analysis of a national all-payers all-claims U.S. insurance database.
9/ The numbers are higher than even the higher estimates published to date, and that’s still based on a conservative estimate. I present the numbers and trends (including for fast-emerging "non-binary" surgeries") in the piece.
10/ I also discuss how gender clinics provide templates to mental health providers for "letters of support" for surgery. The clinic at @seattlechildren provides a template (link & screenshot in article) designed to bypass any concerns about ROGD. The author of the template appears to be a lecturer in creative writing at a university English department.
11/ At least 7 ASPS members are currently being sued by detransitioners. This includes Winnie Tong, who performed a double mastectomy on Kayla Lovdahl when she was 13 years old. Tong did a 30-minute evaluation of Lovdahl when she was just 12, according to her legal complaint.
12/ I discuss the question of legal liability for plastic surgeons, who, though part of a “multidisciplinary team,” often receive patients after they've been affirmed & medicalized. Gender surgeons seem to defer to clinicians at earlier stages in the “affirming” protocol.
13/ Dr. Sheila Nazarian (@DoctorNazarian), a Beverly Hills-based plastic surgeon who has been following the intl' developments in youth gender Rx, told me that colleagues fear "professional and social blowback" from raising questions or concerns about gender surgery on kids.
14/ The current approach “reduces surgeons to mechanics,” Nazarian says, but “we are not highly trained technicians. We are physicians with responsibility for the health and well-being of our patients… You can’t outsource your professional judgement to other clinicians.”
NEW: Azeen Ghorayshi reports in the @nytimes that prominent gender clinician Johanna Olson-Kennedy of @ChildrensLA has refused to publish data from a study on puberty blockers, fearing that the unimpressive results will be "weaponized" by critics of "gender-affirming care." 🧵
Olson-Kennedy told the Times that the kids didn't improve because their mental health was "in really good shape" at the start of the study.
As Ghorayshi notes, this seems to contradict what Olson-Kennedy et al. reported in 2022 about the study's cohort at baseline.
Olson-Kennedy fears the study's results could be cited by critics of pediatric sex "change" in court cases. She doesn't seem to think that, as a medical researcher and clinician, her primary responsibility is to her current and future patients.
NEW: On behalf of @ManhattanInst, @ishapiro @JKetcham91 and I filed an amicus brief in support of Tennessee in U.S. v. Skrmetti, the Supreme Court case dealing with state age restrictions for sex trait modification procedures ("gender-affirming care").
🧵
2/ Our brief is a rebuttal to the amicus brief submitted by "Expert Researchers and Physicians" (McNamara et al.), which is a version of the Yale Integrity Project's white paper, which criticizes the Cass Review.
3/ We argue that McNamara et al. misrepresent the Cass Review, principles of evidence-based medicine, the findings of key studies, and the consistency of pediatric "gender-affirming care" with the wider field of pediatrics on the question of low- or very low-quality evidence.
🚨NEW DOCUMENTS in the Alabama lawsuit over sex "change" age restrictions.
Some very interesting facts now coming to light. 🧵
1/ @wpath sought but did not receive the American Academy of Pediatrics’ (@ameracadpeds) endorsement for its eighth “Standards of Care” (SOC8).
In private emails to WPATH a colleague, SOC-8 lead author Eli Coleman said that this was “highly confidential.”
2/ Coleman appears to admit that it is misleading to claim that medical groups writing amicus briefs against age restriction laws means these groups endorse SOC-8. WPATH tried but failed to get endorsements. (Exhibit #190)
An ongoing @manhattaninst analysis of an all payer, all claims insurance database shows that the 7-year diagnostic persistence rate of adolescent gender dysphoria is between 40-50%.
I discuss this major finding in a new article for @CityJournal 🧵
A central belief justifying medical interventions for gender dysphoric (GD) adolescents is that, unlike childhood GD, GD that persists into (or even arises in) adolescence is almost always permanent. If the condition isn’t permanent, why offer Rx with permanent effects?
First, we analyzed the number of minors with GD in the U.S. between 2017 and 2023. We found 272,181 to 342,476 minors who had the diagnosis.
If we account for the 15% missing claims data in our data set, the range is roughly 320,000 to 400,000.
🚨NEW: I’ve received a FOIA’d file from the Washington State Department of Social and Health Services (@waDSHS) about a 17-year-old receiving puberty blockers.
I’ve seen some extreme cases of medicalization in the past, but this one stands out even for a deep blue state. 1/5
The kid is reported to have a “past [of] extensive abuse [including sexual] and neglect” and to have been through “93 different placements,” which include Qualified Residential Treatment Programs. 2/5
The kid has “borderline intellectual functioning,” with “adaptive scoring in the 2nd percentile.”
A recent study found “a possible detrimental impact [from GnRHa] on IQ. These findings accord with the wider literature on GnRH expression and brain structure and function.”
Unclear whether or how the kid’s use of GnRHa affected IQ in his case. 3/5
"McNamara et al. [the misleadingly titled 'Yale report' criticizing the @thecassreview @Hilary_Cass] is an exceptionally misleading, confused, and fundamentally unprofessional document."
A must-read by @jessesingal, but let me add a few additional details. 🧵
2/ The white paper is a good example of "eminence-based medicine." Its authors seemed to want to use the reputation of @Yale @YaleMed @YaleLawSch to bolster the credibility of the report. But they did so seemingly without first getting the approval of Yale.
3/ On July 1, the report was published and submitted by McNamara, the lead author, into evidence in Boe v. Marshall (Alabama). A little over a week later, the report was republished with a disclosure that the views it contains do not reflect those of the authors' institutions. It's not clear if the revised report, with the disclosure, is the one currently submitted into evidence in the lawsuit.